Evidence map›Paper›PMID 32099408›Full record

ArticleOncoTargets and therapy2020

Expression and Clinical Significance of ERCC1 and XPF in Human Hepatocellular Carcinoma.

Xiaoli Liao, Yongqiang Li, Hualan Li, Wenfeng Huang, Hongxue Wang, Weimin Xie

Open access · goldAbstract read
In one paragraph

Article in OncoTargets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Xiaoli Liao *Department of First Chemotherapy, Affiliated Guangxi Medical University Cancer Hospital, Nanning 530021, People's Republic of China.ORCID 0000-0001-6508-3239
Yongqiang Li *Department of First Chemotherapy, Affiliated Guangxi Medical University Cancer Hospital, Nanning 530021, People's Republic of China.
Hualan Li *Department of First Chemotherapy, Affiliated Guangxi Medical University Cancer Hospital, Nanning 530021, People's Republic of China.
Wenfeng HuangDepartment of Oncology, The Second Affiliated Hospital of Guangxi Medical University, Nanning 530007, People's Republic of China.
Hongxue WangDepartment of Fifth Chemotherapy, Affiliated Guangxi Medical University Cancer Hospital, Nanning 530021, People's Republic of China.
Weimin XieDepartment of Fifth Chemotherapy, Affiliated Guangxi Medical University Cancer Hospital, Nanning 530021, People's Republic of China.
Guangxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the correlation between the ERCC1 and XPF expression and the clinicopathological parameters of hepatocellular carcinoma (HCC) patients through assessment of the expression of the DNA repair genes ERCC1 and XPF.

methodsERCC1 and XPF mRNA expression in HCC (n= 177) and adjacent para-cancer tissues (n=21) were assessed by RT-PCR. The correlation between ERCC1 and XPF expression, clinicopathological features and HCC prognosis were compared.

resultsERCC1 expression in liver cancer tissues was significantly lower than that of adjacent tissues (9.5% (2/21) vs 38.1% (8/21);

conclusionThe expression in ERCC1 and XPF were low in HCC and associated with early relapse after HCC surgery. Low XPF expression may be a potential indicator of a high risk of death.

Indexed as

ERCC1hepatocellular carcinomaprognosisXPF

Identifiers

PMID32099408
PMCPMC7007798
OpenAlexW3004147084

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.